Role of acute exacerbations in skeletal muscle impairment in COPD

References

• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2020 report. 2020; Cited 2020 Aug 25 https://goldcopd.org/wp-content/uploads/2019/12/GOLD-2020-FINAL-ver1.2-03Dec19_WMV.pdf).
   Google Scholar
• Adeloye D, Chua S, Lee C, et al. Global and regional estimates of COPD prevalence: systematic review and meta-analysis. J Glob Health. 2015;5(2):020415
   PubMed Web of Science ®Google Scholar
• WHO. The top 10 causes of death 2018 Cited 2020 Oct 21 2018. https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death.
   Google Scholar
• Vanfleteren L, Spruit MA, Wouters EFM, et al. Management of chronic obstructive pulmonary disease beyond the lungs. Lancet Respir Med. 2016;4(11):911–924.
   PubMed Web of Science ®Google Scholar
• Decramer M, Janssens W. Chronic obstructive pulmonary disease and comorbidities. Lancet Respir Med. 2013;1(1):73–83.
   PubMed Web of Science ®Google Scholar
• Benz E, Trajanoska K, Lahousse L, et al. Sarcopenia in COPD: a systematic review and meta-analysis. Eur Respir Rev. 2019;28(154):154.
   Web of Science ®Google Scholar
• Seymour JM, Spruit MA, Hopkinson NS, et al. The prevalence of quadriceps weakness in COPD and the relationship with disease severity. Eur Respir J. 2010;36(1):81–88.
   PubMed Web of Science ®Google Scholar
• Celli BR, Locantore N, Tal-Singer R, et al., Emphysema and extrapulmonary tissue loss in COPD: a multi-organ loss of tissue phenotype. Eur Respir J. 51(2): 2. 2018. .
   Web of Science ®Google Scholar
• Gosselink R, Troosters T, Decramer M. Peripheral muscle weakness contributes to exercise limitation in COPD. Am J Respir Crit Care Med. 1996;153(3):976–980.
   PubMed Web of Science ®Google Scholar
• Marquis K, Debigare R, Lacasse Y, et al. Midthigh muscle cross-sectional area is a better predictor of mortality than body mass index in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002;166(6):809–813.
   PubMed Web of Science ®Google Scholar
• Decramer M, Gosselink R, Troosters T, et al. Muscle weakness is related to utilization of health care resources in COPD patients. Eur Respir J. 1997;10(2):417–423.
   PubMed Web of Science ®Google Scholar
• Attaway AH, Welch N, Hatipoglu U, et al. Muscle loss contributes to higher morbidity and mortality in COPD : an analysis of national trends. Respirology. 2020. DOI:10.1111/resp.13877
   PubMed Web of Science ®Google Scholar
• Maltais F, Decramer M, Casaburi R, et al. An official American thoracic society/European respiratory society statement: update on limb muscle dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2014;189(9):e15–62.
   PubMed Web of Science ®Google Scholar
• Gosker HR, Lencer NH, Franssen FM, et al. Striking similarities in systemic factors contributing to decreased exercise capacity in patients with severe chronic heart failure or COPD. Chest. 2003;123(5):1416–1424.
   PubMed Web of Science ®Google Scholar
• Caron MA, Debigare R, Dekhuijzen PN, et al. Comparative assessment of the quadriceps and the diaphragm in patients with COPD. J Appl Physiol. 2009;107(3):952–961.
   PubMed Web of Science ®Google Scholar
• Jaitovich A, Barreiro E. Skeletal muscle dysfunction in chronic obstructive pulmonary disease. what we know and can do for our patients. Am J Respir Crit Care Med. 2018;198(2):175–186.
   PubMed Web of Science ®Google Scholar
• Sepulveda-Loyola W, Osadnik C, Phu S, et al. Diagnosis, prevalence, and clinical impact of sarcopenia in COPD: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2020;11(5):1164-1176..
   PubMed Web of Science ®Google Scholar
• Sanders KJ, Kneppers AE, van de Bool C, et al. Cachexia in chronic obstructive pulmonary disease: new insights and therapeutic perspective. J Cachexia Sarcopenia Muscle. 2016;7(1):5–22.
   PubMed Web of Science ®Google Scholar
• Gosker HR, Engelen MPKJ, van Mameren H, et al. Muscle fiber type IIX atrophy is involved in the loss of fat-free mass in chronic obstructive pulmonary disease. Am J Clin Nutr. 2002;76(1):113–119.
   PubMed Web of Science ®Google Scholar
• Langen RC, Gosker HR, Remels AH, et al. Triggers and mechanisms of skeletal muscle wasting in chronic obstructive pulmonary disease. Int J Biochem Cell Biol. 2013;45(10):2245–2256.
   PubMed Web of Science ®Google Scholar
• Kneppers AEM, Langen RCJ, Gosker HR, et al. Increased myogenic and protein turnover signaling in skeletal muscle of chronic obstructive pulmonary disease patients with sarcopenia. J Am Med Dir Assoc. 2017;18(7):637 e631–637 e611.
   Web of Science ®Google Scholar
• Gosker HR, Zeegers MP, Wouters EF, et al. Muscle fibre type shifting in the vastus lateralis of patients with COPD is associated with disease severity: a systematic review and meta-analysis. Thorax. 2007;62(11):944–949.
   PubMed Web of Science ®Google Scholar
• Gosker HR, van Mameren H, van Dijk PJ, et al. Skeletal muscle fibre-type shifting and metabolic profile in patients with chronic obstructive pulmonary disease. Eur Respir J. 2002;19(4):617–625.
   PubMed Web of Science ®Google Scholar
• Rabinovich RA, Bastos R, Ardite E, et al. Mitochondrial dysfunction in COPD patients with low body mass index. Eur Respir J. 2007;29(4):643–650.
   PubMed Web of Science ®Google Scholar
• van den Borst B, Slot IG, Hellwig VA, et al. Loss of quadriceps muscle oxidative phenotype and decreased endurance in patients with mild-to-moderate COPD. J Appl Physiol. 2013;114(9):1319–1328.
   PubMed Web of Science ®Google Scholar
• Remels AH, Schrauwen P, Broekhuizen R, et al. Peroxisome proliferator-activated receptor expression is reduced in skeletal muscle in COPD. Eur Respir J. 2007;30(2):245–252.
   PubMed Web of Science ®Google Scholar
• Leermakers PA, Schols A, Kneppers AEM, et al. Molecular signalling towards mitochondrial breakdown is enhanced in skeletal muscle of patients with chronic obstructive pulmonary disease (COPD). Sci Rep. 2018;8(1):15007.
   PubMedGoogle Scholar
• Celli BR, Barnes PJ. Exacerbations of chronic obstructive pulmonary disease. Eur Respir J. 2007;29(6):1224–1238.
   PubMed Web of Science ®Google Scholar
• Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med. 2011;184(6):662–671
   PubMed Web of Science ®Google Scholar
• Wang Z, Singh R, Miller BE, et al. Sputum microbiome temporal variability and dysbiosis in chronic obstructive pulmonary disease exacerbations: an analysis of the COPDMAP study. Thorax. 2018;73(4):331–338.
   PubMed Web of Science ®Google Scholar
• Mayhew D, Devos N, Lambert C, et al. Longitudinal profiling of the lung microbiome in the AERIS study demonstrates repeatability of bacterial and eosinophilic COPD exacerbations. Thorax. 2018;73(5):422–430.
   PubMed Web of Science ®Google Scholar
• Couillard S, Larivee P, Courteau J, et al. Eosinophils in COPD exacerbations are associated with increased readmissions. Chest. 2017;151(2):366–373.
   PubMed Web of Science ®Google Scholar
• Mathioudakis AG, Janssens W, Sivapalan P, et al. Acute exacerbations of chronic obstructive pulmonary disease: in search of diagnostic biomarkers and treatable traits. Thorax. 2020;75(6):520–527.
   PubMed Web of Science ®Google Scholar
• Viniol C, Vogelmeier CF. Exacerbations of COPD. Eur Respir Rev. 2018;27(147):147.
   Web of Science ®Google Scholar
• Simons SO, Hurst JR. Acute exacerbations of pulmonary diseases (ERS monograph. In: Burgel P-R, Contoli M, López-Campos J, editors. COPD: definition, severity and impact of pulmonary exacerbations. Sheffield: European Respiratory Society; 2017. p. 13–24.
   Google Scholar
• Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128–1138.
   PubMed Web of Science ®Google Scholar
• Spencer S, Jones PW, Group GS. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax. 2003;58(7):589–593.
   PubMed Web of Science ®Google Scholar
• Aaron SD, Donaldson GC, Whitmore GA, et al. Time course and pattern of COPD exacerbation onset. Thorax. 2012;67(3):238–243.
   PubMed Web of Science ®Google Scholar
• Seemungal TA, Donaldson GC, Bhowmik A, et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;161(5):1608–1613.
   PubMed Web of Science ®Google Scholar
• Suissa S, Dell’Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax. 2012;67(11):957–963.
   PubMed Web of Science ®Google Scholar
• Cote CG, Dordelly LJ, Celli BR. Impact of COPD exacerbations on patient-centered outcomes. Chest. 2007;131(3):696–704.
   PubMed Web of Science ®Google Scholar
• Lainscak M, Gosker HR, Schols AM. Chronic obstructive pulmonary disease patient journey: hospitalizations as window of opportunity for extra-pulmonary intervention. Curr Opin Clin Nutr Metab Care. 2013;16(3):278–283.
   PubMed Web of Science ®Google Scholar
• Osadnik CR, Tee VS, Carson-Chahhoud KV, et al. Non-invasive ventilation for the management of acute hypercapnic respiratory failure due to exacerbation of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2017;7:CD004104.
   PubMed Web of Science ®Google Scholar
• Dobler CC, Morrow AS, Beuschel B, et al. Pharmacologic therapies in patients with exacerbation of chronic obstructive pulmonary disease: a systematic review with meta-analysis. Ann Intern Med. 2020;172(6):413–422.
   PubMed Web of Science ®Google Scholar
• van Velzen P, Ter Riet G, Bresser P, et al. Doxycycline for outpatient-treated acute exacerbations of COPD: a randomised double-blind placebo-controlled trial. Lancet Respir Med. 2017;5(6):492–499.
   PubMed Web of Science ®Google Scholar
• Bafadhel M, McKenna S, Terry S, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med. 2012;186(1):48–55.
   PubMed Web of Science ®Google Scholar
• Walters JA, Tan DJ, White CJ, et al. Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2018;3:CD006897.
   PubMedGoogle Scholar
• Nici L, Mammen MJ, Charbek E, et al. Management of chronic obstructive pulmonary disease. An official American thoracic society clinical practice guideline. Am J Respir Crit Care Med. 2020;201(9):e56–e69.
   PubMed Web of Science ®Google Scholar
• Sivapalan P, Ingebrigtsen TS, Rasmussen DB, et al. COPD exacerbations: the impact of long versus short courses of oral corticosteroids on mortality and pneumonia: nationwide data on 67 000 patients with COPD followed for 12 months. BMJ Open Respir Res. 2019;6(1):e000407.
   PubMed Web of Science ®Google Scholar
• Decramer M, de Bock V, Dom R. Functional and histologic picture of steroid-induced myopathy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1996;153(6 Pt 1):1958–1964.
   PubMed Web of Science ®Google Scholar
• Pouw EM, Ten Velde GP, Croonen BH, et al. Early non-elective readmission for chronic obstructive pulmonary disease is associated with weight loss. Clin Nutr. 2000;19(2):95–99.
   PubMed Web of Science ®Google Scholar
• Greening NJ, Harvey-Dunstan TC, Chaplin EJ, et al. Bedside assessment of quadriceps muscle by ultrasound after admission for acute exacerbations of chronic respiratory disease. Am J Respir Crit Care Med. 2015;192(7):810–816
   PubMed Web of Science ®Google Scholar
• Giron R, Matesanz C, Garcia-Rio F, et al. Nutritional state during COPD exacerbation: clinical and prognostic implications. Ann Nutr Metab. 2009;54(1):52–58
   PubMed Web of Science ®Google Scholar
• Guerri R, Gayete A, Balcells E, et al. Mass of intercostal muscles associates with risk of multiple exacerbations in COPD. Respir Med. 2010;104(3):378–388.
   PubMed Web of Science ®Google Scholar
• Perrot L, Greil A, Boirie Y, et al. Prevalence of sarcopenia and malnutrition during acute exacerbation of COPD and after 6 months recovery. Eur J Clin Nutr. 2020. DOI:10.1038/s41430-020-0623-6.
   PubMed Web of Science ®Google Scholar
• Amado CA, Garcia-Unzueta MT, Lavin BA, et al. The ratio serum creatinine/serum cystatin c (a surrogate marker of muscle mass) as a predictor of hospitalization in chronic obstructive pulmonary disease outpatients. Respiration. 2019;97(4):302–309.
   PubMed Web of Science ®Google Scholar
• Hirai K, Tanaka A, Homma T, et al. Serum creatinine/cystatin C ratio as a surrogate marker for sarcopenia in patients with chronic obstructive pulmonary disease. Clin Nutr. 2020. DOI:10.1016/j.clnu.2020.08.010.
   PubMed Web of Science ®Google Scholar
• Tanimura K, Sato S, Sato A, et al. Accelerated loss of antigravity muscles is associated with mortality in patients with COPD. Respiration. 2020;99(4):298–306.
   PubMed Web of Science ®Google Scholar
• Horadagoda C, Dinihan T, Roberts M, et al. Body composition and micronutrient deficiencies in patients with an acute exacerbation of chronic obstructive pulmonary disease. Intern Med J. 2017;47(9):1057–1063.
   PubMed Web of Science ®Google Scholar
• Torres-Sanchez I, Cabrera-Martos I, Diaz-Pelegrina A, et al. Physical and functional impairment during and after hospitalization in subjects with severe COPD exacerbation. Respir Care. 2017;62(2):209–214.
   PubMed Web of Science ®Google Scholar
• Martinez CH, Diaz AA, Meldrum CA, et al. Handgrip strength in chronic obstructive pulmonary disease. associations with acute exacerbations and body composition. Ann Am Thorac Soc. 2017;14(11):1638–1645
   PubMed Web of Science ®Google Scholar
• Ansari K, Keaney N, Taylor I, et al. Muscle weakness, health status and frequency of exacerbations in chronic obstructive pulmonary disease. Postgrad Med J. 2012;88(1041):372–376.
   PubMed Web of Science ®Google Scholar
• Alajlouni D, Bliuc D, Tran T, et al. Decline in muscle strength and performance predicts fracture risk in elderly women and men. J Clin Endocrinol Metab. 2020;105: e3363–e3373.
   PubMed Web of Science ®Google Scholar
• Oliveira CC, Lee AL, McGinley J, et al. Balance and falls in acute exacerbation of chronic obstructive pulmonary disease: a prospective study. COPD. 2017;14(5):518–525.
   PubMedGoogle Scholar
• Hopkinson NS, Tennant RC, Dayer MJ, et al. A prospective study of decline in fat free mass and skeletal muscle strength in chronic obstructive pulmonary disease. Respir Res. 2007;8:25.
   PubMed Web of Science ®Google Scholar
• Vilaro J, Ramirez-Sarmiento A, Martinez-Llorens JM, et al. Global muscle dysfunction as a risk factor of readmission to hospital due to COPD exacerbations. Respir Med. 2010;104(12):1896–1902.
   PubMed Web of Science ®Google Scholar
• Alahmari AD, Kowlessar BS, Patel AR, et al. Physical activity and exercise capacity in patients with moderate COPD exacerbations. Eur Respir J. 2016;48(2):340–349.
   PubMed Web of Science ®Google Scholar
• Spruit MA, Gosselink R, Troosters T, et al. Muscle force during an acute exacerbation in hospitalised patients with COPD and its relationship with CXCL8 and IGF-I. Thorax. 2003;58(9):752–756.
   PubMed Web of Science ®Google Scholar
• Crul T, Spruit MA, Gayan-Ramirez G, et al. Markers of inflammation and disuse in vastus lateralis of chronic obstructive pulmonary disease patients. Eur J Clin Invest. 2007;37(11):897–904.
   PubMed Web of Science ®Google Scholar
• Crul T, Testelmans D, Spruit MA, et al., Gene expression profiling in vastus lateralis muscle during an acute exacerbation of COPD. Cell Physiol Biochem. 25(4–5): 491–500. 2010. .
   PubMed Web of Science ®Google Scholar
• Duan Y, Zhou M, Xiao J, et al. Prediction of key genes and miRNAs responsible for loss of muscle force in patients during an acute exacerbation of chronic obstructive pulmonary disease. Int J Mol Med. 2016;38(5):1450–1462.
   PubMed Web of Science ®Google Scholar
• Pitta F, Troosters T, Probst VS, et al. Physical activity and hospitalization for exacerbation of COPD. Chest. 2006;129(3):536–544.
   PubMed Web of Science ®Google Scholar
• Donaldson GC, Wilkinson TM, Hurst JR, et al. Exacerbations and time spent outdoors in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;171(5):446–452.
   PubMed Web of Science ®Google Scholar
• Hyatt H, Deminice R, Yoshihara T, et al. Mitochondrial dysfunction induces muscle atrophy during prolonged inactivity: A review of the causes and effects. Arch Biochem Biophys. 2019;662:49–60.
   PubMed Web of Science ®Google Scholar
• Dalle S, Koppo K. Is inflammatory signaling involved in disease-related muscle wasting? Evidence from osteoarthritis, chronic obstructive pulmonary disease and type II diabetes. Exp Gerontol. 2020;137:110964.
   PubMed Web of Science ®Google Scholar
• Wouters EF, Groenewegen KH, Dentener MA, et al. Systemic inflammation in chronic obstructive pulmonary disease: the role of exacerbations. Proc Am Thorac Soc. 2007;4(8):626–634.
   PubMedGoogle Scholar
• Vermeeren MAP, Schols A, Wouters EFM. Effects of an acute exacerbation on nutritional and metabolic profile of patients with copd. Eur Respir J. 1997;10:2264–2269.
   PubMed Web of Science ®Google Scholar
• Creutzberg EC, Wouters EF, Vanderhoven-Augustin IM, et al. Disturbances in leptin metabolism are related to energy imbalance during acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;162(4 Pt 1):1239–1245.
   PubMed Web of Science ®Google Scholar
• Wedzicha JAE-C-C, Miravitlles M, Hurst JR, et al., Management of COPD exacerbations: a European respiratory society/American thoracic society guideline. Eur Respir J. 49(3): 3. 2017. .
   Web of Science ®Google Scholar
• Pouw EM, Koerts-de Lang E, Gosker HR, et al. Muscle metabolic status in patients with severe COPD with and without long-term prednisolone. Eur Respir J. 2000;16(2):247–252.
   PubMed Web of Science ®Google Scholar
• Balnis J, Korponay TC, Jaitovich A. AMP-activated protein kinase (AMPK) at the crossroads between co2 retention and skeletal muscle dysfunction in chronic obstructive pulmonary disease (COPD). Int J Mol Sci. 2020;21(3):955.
   Web of Science ®Google Scholar
• Gayan-Ramirez G, Decramer M. Mechanisms of striated muscle dysfunction during acute exacerbations of COPD. J Appl Physiol. 2013;114(9):1291–1299.
   PubMed Web of Science ®Google Scholar
• de Theije C, Costes F, Langen RC, et al. Hypoxia and muscle maintenance regulation: implications for chronic respiratory disease. Curr Opin Clin Nutr Metab Care. 2011;14(6):548–553.
   PubMed Web of Science ®Google Scholar
• Langen RC, Schols AM, Kelders MC, et al. Muscle wasting and impaired muscle regeneration in a murine model of chronic pulmonary inflammation. Am J Respir Cell Mol Biol. 2006;35(6):689–696.
   PubMed Web of Science ®Google Scholar
• Zuo L, Nogueira L, Hogan MC. Effect of pulmonary TNF-alpha overexpression on mouse isolated skeletal muscle function. Am J Physiol Regul Integr Comp Physiol. 2011;301(4):R1025–1031.
   PubMed Web of Science ®Google Scholar
• Li X, Moody MR, Engel D, et al. Cardiac-specific overexpression of tumor necrosis factor-alpha causes oxidative stress and contractile dysfunction in mouse diaphragm. Circulation. 2000;102(14):1690–1696.
   PubMed Web of Science ®Google Scholar
• Buck M, Chojkier M. Muscle wasting and dedifferentiation induced by oxidative stress in a murine model of cachexia is prevented by inhibitors of nitric oxide synthesis and antioxidants. Embo J. 1996;15(8):1753–1765.
   PubMed Web of Science ®Google Scholar
• Matthys P, Dijkmans R, Proost P, et al. Severe cachexia in mice inoculated with interferon-gamma-producing tumor cells. Int J Cancer. 1991;49(1):77–82.
   PubMed Web of Science ®Google Scholar
• Guttridge DC, Mayo MW, Madrid LV, et al. NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science. 2000;289(5488):2363–2366.
   PubMed Web of Science ®Google Scholar
• Li YP, Schwartz RJ, Waddell ID, et al. Skeletal muscle myocytes undergo protein loss and reactive oxygen-mediated NF-kappaB activation in response to tumor necrosis factor alpha. Faseb J. 1998;12(10):871–880.
   PubMed Web of Science ®Google Scholar
• Adams V, Mangner N, Gasch A, et al. Induction of MuRF1 is essential for TNF-alpha-induced loss of muscle function in mice. J Mol Biol. 2008;384(1):48–59.
   PubMed Web of Science ®Google Scholar
• De Larichaudy J, Zufferli A, Serra F, et al. TNF-alpha- and tumor-induced skeletal muscle atrophy involves sphingolipid metabolism. Skelet Muscle. 2012;2(1):2.
   PubMedGoogle Scholar
• Langen RCJ, Van Der Velden JLJ, Schols AMWJ, et al. Tumor necrosis factor-alpha inhibits myogenic differentiation through MyoD protein destabilization. Faseb J. 2004;in press. DOI:10.1096/fj.03-0251com.
   PubMed Web of Science ®Google Scholar
• Langen RC, Haegens A, Vernooy JH, et al. NF-kappaB activation is required for the transition of pulmonary inflammation to muscle atrophy. Am J Respir Cell Mol Biol. 2012;47(3):288–297.
   PubMed Web of Science ®Google Scholar
• Cai D, Frantz JD, Tawa NE Jr., et al. IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell. 2004;119(2):285–298.
   PubMed Web of Science ®Google Scholar
• Remels AH, Gosker HR, Schrauwen P, et al. TNF-alpha impairs regulation of muscle oxidative phenotype: implications for cachexia? Faseb J. 2010;24(12):5052–5062.
   PubMed Web of Science ®Google Scholar
• Tang K, Wagner PD, Breen EC. TNF-alpha-mediated reduction in PGC-1alpha may impair skeletal muscle function after cigarette smoke exposure. J Cell Physiol. 2009;222(2):320–327.
   Web of Science ®Google Scholar
• Remels AH, Gosker HR, Bakker J, et al. Regulation of skeletal muscle oxidative phenotype by classical NF-kappaB signalling. Biochim Biophys Acta. 2013;1832(8):1313–1325.
   PubMed Web of Science ®Google Scholar
• Hakvoort TB, Moerland PD, Frijters R, et al. Interorgan coordination of the murine adaptive response to fasting. J Biol Chem. 2011;286(18):16332–16343.
   PubMed Web of Science ®Google Scholar
• Zhao J, Brault JJ, Schild A, et al. FoxO3 coordinately activates protein degradation by the autophagic/lysosomal and proteasomal pathways in atrophying muscle cells. Cell Metab. 2007;6(6):472–483.
   PubMed Web of Science ®Google Scholar
• Shah OJ, Anthony JC, Kimball SR, et al. 4E-BP1 and S6K1: translational integration sites for nutritional and hormonal information in muscle. Am J Physiol Endocrinol Metab. 2000;279(4):E715–729.
   PubMed Web of Science ®Google Scholar
• Mofarrahi M, Guo Y, Haspel JA, et al. Autophagic flux and oxidative capacity of skeletal muscles during acute starvation. Autophagy. 2013;9(10):10.
   Web of Science ®Google Scholar
• Henriksson J. The possible role of skeletal muscle in the adaptation to periods of energy deficiency. Eur J Clin Nutr. 1990;44(Suppl 1(4)):55–64.
   PubMedGoogle Scholar
• Oost LJ, Kustermann M, Armani A, et al. Fibroblast growth factor 21 controls mitophagy and muscle mass. J Cachexia Sarcopenia Muscle. 2019;10(3):630–642.
   PubMed Web of Science ®Google Scholar
• Miyazaki M, Shimozuru M, Tsubota T. Skeletal muscles of hibernating black bears show minimal atrophy and phenotype shifting despite prolonged physical inactivity and starvation. PLoS One. 2019;14(4):e0215489.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci (Lond). 1998;94(6):557–572.
   PubMed Web of Science ®Google Scholar
• de Theije CC, Schols A, Lamers WH, et al. Glucocorticoid receptor signaling impairs protein turnover regulation in hypoxia-induced muscle atrophy in male mice. Endocrinology. 2018;159(1):519–534.
   PubMed Web of Science ®Google Scholar
• Gayan-Ramirez G, Vanderhoydonc F, Verhoeven G, et al. Acute treatment with corticosteroids decreases IGF-1 and IGF-2 expression in the rat diaphragm and gastrocnemius. Am J Respir Crit Care Med. 1999;159(1):283–289.
   PubMed Web of Science ®Google Scholar
• Gilson H, Schakman O, Combaret L, et al. Myostatin gene deletion prevents glucocorticoid-induced muscle atrophy. Endocrinology. 2007;148(1):452–460.
   PubMed Web of Science ®Google Scholar
• Verhees KJ, Schols AM, Kelders MC, et al. Glycogen synthase kinase-3beta is required for the induction of skeletal muscle atrophy. Am J Physiol Cell Physiol. 2011;301(5):C995–C1007.
   PubMed Web of Science ®Google Scholar
• Castillero E, Alamdari N, Lecker SH, et al. Suppression of atrogin-1 and MuRF1 prevents dexamethasone-induced atrophy of cultured myotubes. Metabolism. 2013;62(10):1495–1502.
   PubMed Web of Science ®Google Scholar
• Pansters NA, Langen RC, Wouters EF, et al. Synergistic stimulation of myogenesis by glucocorticoid and IGF-I signaling. J Appl Physiol. 2013;114(9):1329–1339.
   PubMed Web of Science ®Google Scholar
• van RH B, Dekhuijzen PN, Folgering HT, et al. Effects of long-term low-dose methylprednisolone on rat diaphragm function and structure. Muscle Nerve. 1997;20(8):983–990.
   PubMed Web of Science ®Google Scholar
• Huang Y, Chen K, Ren Q, et al. Dihydromyricetin attenuates dexamethasone-induced muscle atrophy by improving mitochondrial function via the PGC-1alpha pathway. Cell Physiol Biochem. 2018;49(2):758–779.
   PubMedGoogle Scholar
• You YN, Short KR, Jourdan M, et al. The effect of high glucocorticoid administration and food restriction on rodent skeletal muscle mitochondrial function and protein metabolism. PLoS One. 2009;4(4):e5283.
   PubMed Web of Science ®Google Scholar
• Troncoso R, Paredes F, Parra V, et al. Dexamethasone-induced autophagy mediates muscle atrophy through mitochondrial clearance. Cell Cycle. 2014;13(14):2281–2295.
   PubMed Web of Science ®Google Scholar
• de Theije CC, Langen RC, Lamers WH, et al. Distinct responses of protein turnover regulatory pathways in hypoxia- and semistarvation-induced muscle atrophy. Am J Physiol Lung Cell Mol Physiol. 2013;305(1):L82–91.
   PubMed Web of Science ®Google Scholar
• de Theije CC, Schols A, Lamers WH, et al. Hypoxia impairs adaptation of skeletal muscle protein turnover- and AMPK signaling during fasting-induced muscle atrophy. PLoS One. 2018;13(9):e0203630.
   PubMed Web of Science ®Google Scholar
• de Theije CC, Langen RC, Lamers WH, et al. Differential sensitivity of oxidative and glycolytic muscles to hypoxia-induced muscle atrophy. J Appl Physiol. 2015;118(2):200–211.
   PubMed Web of Science ®Google Scholar
• Slot IG, Schols AM, de Theije CC, et al. Alterations in skeletal muscle oxidative phenotype in mice exposed to 3 weeks of normobaric hypoxia. J Cell Physiol. 2016;231(2):377–392.
   PubMed Web of Science ®Google Scholar
• Riva C, Chevrier C, Pasqual N, et al. Bcl- 2/Bax protein expression in heart, slow-twitch and fast-twitch muscles in young rats growing under chronic hypoxia conditions. Mol Cell Biochem. 2001;226(1–2):9–16.
   PubMed Web of Science ®Google Scholar
• Di Carlo A, De Mori R, Martelli F, et al. Hypoxia inhibits myogenic differentiation through accelerated MyoD degradation. J Biol Chem. 2004;279(16):16332–16338.
   PubMed Web of Science ®Google Scholar
• Mancinelli R, Pietrangelo T, La Rovere R, et al. Cellular and molecular responses of human skeletal muscle exposed to hypoxic environment. J Biol Regul Homeost Agents. 2011;25(4):635–645.
   PubMed Web of Science ®Google Scholar
• Atherton PJ, Greenhaff PL, Phillips SM, et al. Control of skeletal muscle atrophy in response to disuse: clinical/preclinical contentions and fallacies of evidence. Am J Physiol Endocrinol Metab. 2016;311(3):E594–604.
   PubMed Web of Science ®Google Scholar
• Theeuwes WF, Pansters NAM, Gosker HR, et al. Recovery of muscle mass and muscle oxidative phenotype following disuse does not require GSK-3 inactivation. Biochim Biophys Acta Mol Basis Dis. 2020;1866(6):165740.
   PubMed Web of Science ®Google Scholar
• Leermakers PA, Kneppers AEM, Schols A, et al. Skeletal muscle unloading results in increased mitophagy and decreased mitochondrial biogenesis regulation. Muscle Nerve. 2019. DOI:10.1002/mus.26702.
   PubMed Web of Science ®Google Scholar
• Koncarevic A, Jackman RW, Kandarian SC. The ubiquitin-protein ligase Nedd4 targets Notch1 in skeletal muscle and distinguishes the subset of atrophies caused by reduced muscle tension. Faseb J. 2007;21(2):427–437.
   PubMed Web of Science ®Google Scholar
• Guo Y, Gosker HR, Schols AM, et al. Autophagy in locomotor muscles of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;188(11):1313–1320.
   PubMed Web of Science ®Google Scholar
• Pansters NA, Schols AM, Verhees KJ, et al. Muscle-specific GSK-3beta ablation accelerates regeneration of disuse-atrophied skeletal muscle. Biochim Biophys Acta. 2015;1852(3):490–506.
   PubMed Web of Science ®Google Scholar
• Gram M, Dahl R, Dela F. Physical inactivity and muscle oxidative capacity in humans. Eur J Sport Sci. 2014;14(4):376–383.
   PubMed Web of Science ®Google Scholar
• Kang C, Ji LLPGC. 1alpha overexpression via local transfection attenuates mitophagy pathway in muscle disuse atrophy. Free Radic Biol Med. 2016;93:32–40.
   PubMed Web of Science ®Google Scholar
• Cannavino J, Brocca L, Sandri M, et al. PGC1-alpha over-expression prevents metabolic alterations and soleus muscle atrophy in hindlimb unloaded mice. J Physiol. 2014;592(20):4575–4589.
   PubMed Web of Science ®Google Scholar
• Gosker HR, Langen RC, Bracke KR, et al. Extrapulmonary manifestations of chronic obstructive pulmonary disease in a mouse model of chronic cigarette smoke exposure. Am J Respir Cell Mol Biol. 2009;40(6):710–716.
   PubMed Web of Science ®Google Scholar
• Rinaldi M, Maes K, De Vleeschauwer S, et al. Long-term nose-only cigarette smoke exposure induces emphysema and mild skeletal muscle dysfunction in mice. Dis Model Mech. 2012;5(3):333–341.
   PubMed Web of Science ®Google Scholar
• Caron MA, Morissette MC, Theriault ME, et al. Alterations in skeletal muscle cell homeostasis in a mouse model of cigarette smoke exposure. PLoS One. 2013;8(6):e66433.
   PubMed Web of Science ®Google Scholar
• Ceelen JJM, Schols A, van Hoof SJ, et al. Differential regulation of muscle protein turnover in response to emphysema and acute pulmonary inflammation. Respir Res. 2017;18(1):75.
   PubMedGoogle Scholar
• Mattson JP, Poole DC, Hahn SA, et al. Maximal force is unaffected by emphysema-induced atrophy in extensor digitorium longus. Respir Physiol Neurobiol. 2008;161(2):119–124.
   PubMed Web of Science ®Google Scholar
• Zhang XL, Pang BS, Hou XL, et al. Oxidative stress and peripheral skeletal muscle dysfunction in rats with emphysema. Chin Med J (Engl). 2010;123(1):40–44.
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Fujinawa R, Ota F, et al., A single dose of lipopolysaccharide into mice with emphysema mimics human chronic obstructive pulmonary disease exacerbation as assessed by micro-computed tomography. Am J Respir Cell Mol Biol. 49(6): 971–977. 2013. .
   PubMed Web of Science ®Google Scholar
• Gou X, Zhang Q, More S, et al., Repeated exposure to streptococcus pneumoniae exacerbates chronic obstructive pulmonary disease. Am J Pathol. 189(9): 1711–1720. 2019. .
   PubMed Web of Science ®Google Scholar
• Vlahos R, Bozinovski S. Preclinical murine models of chronic obstructive pulmonary disease. Eur J Pharmacol. 2015;759:265–271.
   PubMed Web of Science ®Google Scholar
• Ceelen JJM, Schols A, Thielen NGM, et al. Pulmonary inflammation-induced loss and subsequent recovery of skeletal muscle mass require functional poly-ubiquitin conjugation. Respir Res. 2018;19(1):80.
   PubMedGoogle Scholar
• Files DC, D’Alessio FR, Johnston LF, et al. A critical role for muscle ring finger-1 in acute lung injury-associated skeletal muscle wasting. Am J Respir Crit Care Med. 2012;185(8):825–834.
   PubMed Web of Science ®Google Scholar
• Haegens A, Schols AM, Gorissen SH, et al. NF-kappaB activation and polyubiquitin conjugation are required for pulmonary inflammation-induced diaphragm atrophy. Am J Physiol Lung Cell Mol Physiol. 2012;302(1):L103–110.
   PubMed Web of Science ®Google Scholar
• Ceelen JJM, Schols A, Kneppers AEM, et al., Altered protein turnover signaling and myogenesis during impaired recovery of inflammation-induced muscle atrophy in emphysematous mice. Sci Rep. 8(1): 10761. 2018. .
   PubMedGoogle Scholar
• Chan SMH, Cerni C, Passey S, et al. Cigarette smoking exacerbates skeletal muscle injury without compromising its regenerative capacity. Am J Respir Cell Mol Biol. 2020;62(2):217–230.
   PubMed Web of Science ®Google Scholar
• Balnis J, Korponay TC, Vincent CE, et al. IL-13-driven pulmonary emphysema leads to skeletal muscle dysfunction attenuated by endurance exercise. J Appl Physiol. 2020;128(1):134–148.
   PubMed Web of Science ®Google Scholar
• Graber TG, Rawls BL, Tian B, et al. Repetitive TLR3 activation in the lung induces skeletal muscle adaptations and cachexia. Exp Gerontol. 2018;106:88–100.
   PubMed Web of Science ®Google Scholar
• Abdulai RM, Jensen TJ, Patel NR, et al. Deterioration of limb muscle function during acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;197(4):433–449.
   PubMed Web of Science ®Google Scholar
• Gayan-Ramirez G. Relevance of nutritional support and early rehabilitation in hospitalized patients with COPD. J Thorac Dis. 2018;10(Suppl 12):S1400–S1414.
   PubMedGoogle Scholar
• Jones SE, Barker RE, Nolan CM, et al. Pulmonary rehabilitation in patients with an acute exacerbation of chronic obstructive pulmonary disease. J Thorac Dis. 2018;10(Suppl 12):S1390–S1399.
   PubMed Web of Science ®Google Scholar
• Spencer L. Pulmonary rehabilitation for patients with acute chronic obstructive pulmonary disease exacerbations: is the evidence strengthening? Curr Opin Pulm Med. 2018;24(2):147–151.
   PubMed Web of Science ®Google Scholar
• Dobler CC, Morrow AS, Farah MH, et al. Nonpharmacologic therapies in patients with exacerbation of chronic obstructive pulmonary disease: a systematic review with meta-analysis. Mayo Clin Proc. 2020;95(6):1169–1183.
   PubMed Web of Science ®Google Scholar
• Troosters T, Probst VS, Crul T, et al. Resistance training prevents deterioration in quadriceps muscle function during acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010;181(10):1072–1077.
   PubMed Web of Science ®Google Scholar
• Martin-Salvador A, Colodro-Amores G, Torres-Sanchez I, et al. Physical therapy intervention during hospitalization in patients with acute exacerbation of chronic obstructive pulmonary disease and pneumonia: a randomized clinical trial. Med Clin (Barc). 2016;146(7):301–304.
   PubMed Web of Science ®Google Scholar
• Knaut C, Mesquita CB, Caram LM, et al. Assessment of aerobic exercise adverse effects during COPD exacerbation hospitalization. Can Respir J. 2017;5937908:2017.
   Google Scholar
• Greening NJ, Williams JEA, Hussain SF, et al. An early rehabilitation intervention to enhance recovery during hospital admission for an exacerbation of chronic respiratory disease: randomised controlled trial.BMJ. 2014; 349:g4315.
   Google Scholar
• Spruit MA, Singh SJ, Rochester CL, et al., Pulmonary rehabilitation for patients with COPD during and after an exacerbation-related hospitalisation: back to the future? Eur Respir J. 51(1): 1. 2018. .
   Google Scholar
• Machado A, Oliveira A, Valente C, et al. Effects of a community-based pulmonary rehabilitation programme during acute exacerbations of chronic obstructive pulmonary disease - A quasi-experimental pilot study. Pulmonology. 2020;26(1):27–38.
   PubMed Web of Science ®Google Scholar
• Abdellaoui A, Prefaut C, Gouzi F, et al. Skeletal muscle effects of electrostimulation after COPD exacerbation: a pilot study. Eur Respir J. 2011;38(4):781–788.
   PubMed Web of Science ®Google Scholar
• Saudny Unterberger H, Martin JG, Gray Donald K. Impact of nutritional support on functional status during an acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1997;156(3 Pt 1):794–799.
   PubMed Web of Science ®Google Scholar
• Vermeeren MA, Wouters EF, Geraerts-Keeris AJ, et al. Nutritional support in patients with chronic obstructive pulmonary disease during hospitalization for an acute exacerbation; a randomized controlled feasibility trial. Clin Nutr. 2004;23(5):1184–1192.
   PubMed Web of Science ®Google Scholar
• Ogasawara T, Marui S, Miura E, et al. Effect of eicosapentaenoic acid on prevention of lean body mass depletion in patients with exacerbation of chronic obstructive pulmonary disease: A prospective randomized controlled trial. Clin Nutr ESPEN. 2018;28:67–73.
   PubMed Web of Science ®Google Scholar
• Polkey MI, Praestgaard J, Berwick A, et al. Activin type II receptor blockade for treatment of muscle depletion in chronic obstructive pulmonary disease. A randomized trial. Am J Respir Crit Care Med. 2019;199(3):313–320
   PubMed Web of Science ®Google Scholar
• Passey SL, Hansen MJ, Bozinovski S, et al. Emerging therapies for the treatment of skeletal muscle wasting in chronic obstructive pulmonary disease. Pharmacol Ther. 2016;166:56–70.
   PubMed Web of Science ®Google Scholar
• Vanfleteren LE, Spruit MA, Groenen M, et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187(7):728–735.
   PubMed Web of Science ®Google Scholar
• Wall BT, Dirks ML, van Loon LJ. Skeletal muscle atrophy during short-term disuse: implications for age-related sarcopenia. Ageing Res Rev. 2013;12(4):898–906.
   PubMed Web of Science ®Google Scholar